Bharat Biotech, a global leader in vaccine innovation and developer of vaccines for infectious diseases, today announced the results from the highly anticipated trial studying the immunogenicity and safety of the COVAXIN® (BBV152) a whole-virion inactivated COVID-19 vaccine as a booster dose.
Home COVAXIN® (BBV152) booster dose study shows Promising Results COVAXIN® (BBV152) booster dose study shows Promising Results